Indian pharmaceutical billionaire Kiran Mazumdar-Shaw is positioning her company, Biocon, to become the world’s leading insulin supplier as major global drugmakers increasingly redirect investment toward high-growth obesity and weight-loss treatments. The strategy comes amid rising global diabetes rates and growing concerns about long-term insulin accessibility, creating a significant market opportunity for manufacturers capable of delivering affordable supplies at scale. Biocon has stated that it aims to become “the insulin company of the world” as competitors prioritize newer GLP-1 therapies.
According to company executives, Biocon is expanding production capacity and leveraging its established presence across more than 80 markets to capture a larger share of the global insulin market. The company is investing in manufacturing upgrades at its Malaysia facility, with plans to double insulin drug-product capacity by fiscal year 2027 and further expand production capabilities in subsequent years. Industry estimates cited by Business Standard place the global insulin market at between $29 billion and $31 billion, underscoring the scale of the opportunity.
The shift comes as leading pharmaceutical groups including Novo Nordisk, Eli Lilly, and Sanofi increasingly prioritize obesity and diabetes treatments based on GLP-1 technology, which have become some of the fastest-growing products in the healthcare industry. Bloomberg notes that manufacturing constraints and higher profit margins in the GLP-1 segment are prompting some companies to allocate resources away from traditional insulin products, creating supply gaps that firms such as Biocon hope to fill.
For India’s pharmaceutical sector, Biocon’s ambitions highlight the country’s growing role in supplying affordable medicines to global markets. Analysts say the company’s focus on insulin could strengthen access to diabetes treatment in both developed and emerging economies while enhancing India’s position in the global biologics industry. With worldwide diabetes cases projected to rise significantly over the next decade, demand for reliable and cost-effective insulin supplies is expected to remain strong, creating a long-term growth opportunity for manufacturers capable of scaling production efficiently.
